In April 2023, the FDA issued a Complete Response Letter for the biosimilar, citing manufacturing issues at its Reykjavik, Iceland, facility
GHK-Cu (glycyl-L-histidyl-L-lysine bound to copper(II)) has been used for decades in low-concentration topical cosmetics with a generally favorable tolerability record, but there is almost no published human adverse-event data especially for injectable or systemic research use
The optimal treatment protocol depends on your specific health status and wellness goals
Amino acids V12 (putative oxyanion hole), F112 (active site architecture), N108 (flavonoid binding) and C13 (GSH stabilization) were fully randomized by site saturation mutagenesis (NNK codons), and the created Pt GSTF8 variants were tested for conversion of flavan-3,3,4-triol ( 4 ) to cyanidin ( 8 ), and for their GSH-transferase activity towards CDNB ( 5 ) as a control of catalytic competence